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Abstract
Background: Myocardin (MYOCD), a potent transcriptional coactivator of smooth muscle (SM) and cardiac genes, is
upregulated in failing myocardium in animal models and human end-stage heart failure (HF). However, the molecular and
functional consequences of myocd upregulation in HF are still unclear.
Methodology/Principal Findings: The goal of the present study was to investigate if targeted inhibition of upregulated
expression of myocd could influence failing heart gene expression and function. To this end, we used the doxorubicin (Dox)-
induced diastolic HF (DHF) model in neonatal piglets, in which, as we show, not only myocd but also myocd-dependent SM-
marker genes are highly activated in failing left ventricular (LV) myocardium. In this model, intra-myocardial delivery of
short-hairpin RNAs, designed to target myocd variants expressed in porcine heart, leads on day 2 post-delivery to: (1) a
decrease in the activated expression of myocd and myocd-dependent SM-marker genes in failing myocardium to levels seen
in healthy control animals, (2) amelioration of impaired diastolic dysfunction, and (3) higher survival rates of DHF piglets.
The posterior restoration of elevated myocd expression (on day 7 post-delivery) led to overexpression of myocd-dependent
SM-marker genes in failing LV-myocardium that was associated with a return to altered diastolic function.
Conclusions/Significance: These data provide the first evidence that a moderate inhibition (e.g., normalization) of the
activated MYOCD signaling in the diseased heart may be promising from a therapeutic point of view.
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Introduction
Despite diagnostic and therapeutic advances in clinical
cardiology, heart failure (HF), both systolic and diastolic, remains
a leading cause of morbidity and mortality in developed countries.
The precise stimuli for and mechanisms of ventricular remodeling
in acquired HF are not yet clearly delineated. Early studies used a
candidate gene approach focused mainly on factors within
adrenergic and renin-angiotensin pathways. A recent trend, based
on a gene expression topology of the developing and diseased
heart, has resulted in the re-interpretation of pathological
ventricular remodeling in terms of rearrangement of key gene
regulatory networks and downstream signaling pathways that are
imbalanced, attenuated, or abnormally activated in failing
myocardium [1,2,3,4,5]. A prominent example of the latter is a
serum response factor (SRF)-myocardin (MYOCD) signaling
cascade, which is expressed by and modulates gene expression of
embryonic, fetal and postnatal cardiomyocytes (reviewed in
[6,7,8,9,10,11,12]).
The ability of MYOCD to contribute to heart development and
cardiomyocyte differentiation is conserved, although to a different
extent, in frogs, chickens, and mammals. Inhibition of endogenous
myocd expression/function in Xenopus [13,14] and chick [15]
embryos is associated with impaired heart development. By
contrast, in mouse embryos total knockout [16] or cardio-
restricted inactivation [17] of the myocd gene does not alter heart
development. However, after birth mutant mice with a condition-
ally inactivated myocd gene develop dilated cardiomyopathy
accompanied by impaired cardiomyocyte structural organization
and severely depressed systolic function. In chimeric myocd
knockout mice, generated by injection of myocd2/2 embryonic
stem cells into myocd+/+ blastocysts, myocd2/2 cells almost
completely fail to contribute to formation of ventricular myocar-
dium, although myocd2/2-derived myocytes were phenotypically
normal [18]. The results suggest that in fetal mouse heart myocd is
specifically required for functional differentiation of ventricular
cardiomyocytes.
Despite its importance in heart development and cardiomyocyte
differentiation, myocd activation appears to be involved in the
adaptive hypertrophic response of the heart during early postnatal
development [19] and aging [20]. In fact, myocd expression and
activity are enhanced in cardiomyocytes upon hypertrophic stimuli
[21,22,23]. In addition, in vitro forced expression of myocd in mouse
neonatal cardiomyocytes increases cell size and activates tran-
scription of established myocd targets, such as smooth muscle (SM)
a-actin (ACTA2) and SM myosin heavy chain (MYH11), along
with a set of cardiac hypertrophy-associated genes [21]. Myocd
inactivation, by dominant-negative mutant [21] or interfering
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RNA [22], inhibits agonist-induced hypertrophy in cardiomyo-
cytes, but does not provoke either disruption of sarcomeric
structure or cardiomyocyte atrophy. In neonatal piglet heart, in
vivo forced myocd expression upregulates genes for SM22a/
transgelin (TAGLN) and fetal muscle light chain 3f myosin
associated with transiently impaired systolic function [24]. In
postnatal mouse heart, conditional knockdown of myocd leads to
the rapid-onset of HF due to dilated cardiomyopathy which is
associated with attenuated expression of SRF/MYOCD-regulated
cardiac genes and activation of pro-apoptotic factors in failing
myocardium [17]. Taken together, these observations suggested
that both MYOCD redundancy and deficiency in postnatal
cardiomyocytes affect cardiac performance.
In addition to its role in adaptive gene expression and
maintenance of cardiac function, myocd has also been implicated
in the response of the postnatal/adult heart to pathological stresses
during hypertrophic remodeling [21,25], cardiomyopathic pro-
gression [26] and at end-stage HF [19,21]. All of these conditions
are characterized by upregulation of myocd expression in failing left
ventricular (LV) myocardium. In addition, myocd targets, such as
ACTA2 [27,28], SM-calponin (CNN1), and MYH11 [29], are
also upregulated in failing myocardium in both animal models and
patients. Although this correlative evidence links MYOCD
signaling to acquired pathological conditions, the role that myocd
gene activation plays in HF conditions in vivo has yet to be
determined.
A provocative hypothesis was that myocd overexpression might
represent a maladaptive response of ventricular myocardium to
pathological remodeling [8,24]. The goal of the present study was,
therefore, to investigate if targeted inhibition of upregulated
expression of myocd in failing ventricular myocardium could
normalize dysregulated MYOCD signaling pathways and restore,
at least in part, impaired cardiac function. To this end, we used the
doxorubicin (Dox)-induced diastolic HF (DHF) model in neonatal
piglets, in which upregulation of myocd was established as a HF-
related feature [19]. In the present work, we extend these results
demonstrating that not only myocd but also myocd-dependent SM-
marker genes are highly activated in failing LV-myocardium of
Dox-injected piglets.
In vivo silencing of endogenous myocd expression by short-hairpin
(sh) interfering RNAs at advanced stages of DHF in piglets resulted
in downregulation of myocd-dependent SM-gene expression in
failing myocardium. Such adjusting of MYOCD and SM-target
levels to the scores measured in non-failing controls resulted in
restoring diastolic function and extending the survival of failing
animals. These data provide the first evidence that a moderate
inhibition (e.g., normalization) of activated MYOCD signaling in
the diseased heart may be promising from a therapeutic point of
view.
Materials and Methods
Animals and experimental design
Early neonatal ‘‘Large White’’ piglets were obtained from a
local commercial breeder (La Corun˜a, Spain), maintained in a
conventional Nu¨rtinger nursery system for days 8 after birth, and
randomized in seven groups according to experimental design
(Fig. 1A). A diastolic heart failure (DHF) model was established in
8-day-old neonatal piglets by an i.v. injection of cardio-toxic agent,
Doxorubicin (Dox; Sigma, Madrid, Spain) of a single dose of
2.0 mg/kg as previously described [30]. Animals injected with
normal isotonic saline (PBS) were used as controls. Some Dox-
injected (Group I) and PBS-injected (Group II) animals were not
additionally manipulated, but others were subjected to intramyo-
cardial delivery of plasmids expressing either short hairpin (sh)
myocd-silencing (Group III and V) or sh-scrambled (Group IV, VI,
and VII) vectors before the planned end of the study. At the end of
each experimental run (see Fig. 1A), ECGs and cardiac output
(PiCCO device, Pulsion AG, Germany) were monitored in closed-
chest piglets, while measurements of LV end-systolic (ESP) and
end-diastolic pressure (EDP) were performed in open-chest piglets
using a Dra¨ger UM3.1 pressure transducer and a recording device
(Dra¨gerwerk AG, Germany) as described in [30]. Then piglets
were euthanized to harvest cardiac tissues for RNA and protein
isolation. Piglets were used in accordance with the European
Commission Directive 86/609/EEC and all protocols were
approved by the Institutional Animal Care and Use Ethics
Committee (permit number: PI 1–2008; University of La Corun˜a,
La Corun˜a, Spain).
RNA isolation
For total RNA isolation, deep-frozen tissue/cell samples were
directly disrupted in RLT buffer (Qiagen, Madrid, Spain) using a
high-speed rotor-stator homogenizer (Ultra-Turrax T8, Ger-
many), digested with Proteinase K (Qiagen), loaded onto RNeasy
Mini/Midi columns (Qiagen), subjected to on-column digestion of
DNA with RNase-free DNase (Qiagen), and processed in
accordance with the manufacturer’s recommendations. Resulting
RNA preparations were ethanol-precipitated, resolved in RNase-
free H2O, and kept at 280uC. RNA yield and purity was
determined spectrophotometrically at 260–280 nm and RNA
integrity was verified by running samples on 1.2% agarose gels and
staining with ethidium bromide.
Microarray
Total RNAs isolated from LV biopsies of three failing (i.e., Dox-
injected) and three non-failing (i.e., PBS-injected) piglets were
independently hybridized on the Affymetrix GeneChipH Porcine
Genome Array (Affymetrix, Santa Clara, US), which contains
23,937 probe sets interrogating 23,256 transcripts and represent-
ing 20,201 genes of S. scrofa. Sample processing, array hybridiza-
tion, scanning, and quantification were performed at the
Affymetrix Service Provider and Core Facility, ‘‘KFB - Center
of Excellence for Fluorescent Bioanalytics’’ (University of Regens-
burg, Regensburg, Germany; www.kfb-regensburg.de). Genes
were considered to be differentially expressed if a change of at
least 2-fold was observed for evaluated (failing versus non-failing)
comparisons at a p-value cutoff of 0.05. The microarray data have
been deposited in the NCBI’s Gene Expression Omnibus (GEO;
[31]) and are accessible through GEO Series accession number
GSE30110 (http://www.ncbi.nlm.nih.gov/geo).
Design and generation of short-hairpin RNA plasmids
Nine short-hairpin (sh) 19-mer sequences located throughout
the full-length of the porcine myocd-B mRNA (Fig. 1B) were
designed using the basic tools [32,33]. The sh-RNAs were
designed to target sites devoid of single nucleotide polymorphisms,
and correspond to splice myocd-A/B variants identified in pig
myocardium [19,24]. Each oligonucleotide pair included (Fig. 1C):
a BamHI overhang on the 59 end of the duplex, the 19 nucleotides
of the sh-RNA sense strand, a loop sequence, the 19 nucleotides of
the RNA antisense strand, a Pol III termination site of 6
consecutive thymidine residues, and a Hind III overhang on the
39 end of the duplex. The scrambled sh-RNA sequence 1 (sh-scr1,
see Table 1) was constructed in an identical manner; the sh-scr2
was from Ambion. Annealed oligonucleotides encoding sh-RNAs
were cloned in a pSilencer 2.1-U6 puro vector in accordance with
the manufacturer’s protocol (Ambion, Cambridgeshire, UK).
Myocardin Signaling in the Failing Heart
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Resulting plasmids were verified by sequencing as a service
provided by Secugen (Madrid, Spain). For transfections, plasmids
were purified using a PureLink HiPure plasmid filter purification
kit (Invitrogen, Barcelona, Spain) according to the manufacturer’s
protocol.
Cell culture and transfection in vitro
COS-7 and porcine aortic smooth muscle cells (PAOSMCs)
were purchased from the European Collection of Cell Cultures
(ECACC; Salisbury, UK). COS-7 cells were cultured in
Dulbecco’s modified Eagle’s Medium (Gibco, Barcelona, Spain)
supplemented with 10% fetal bovine serum (FBS) and penicillin–
streptomycin–glutamine (Gibco) under standard tissue culture
conditions at 37uC. Cells were trypsinized at 70–80% confluence,
cell numbers were determined using an automated cell counter
(Countess, Invitrogen, Barcelona, Spain) and 80,000 cells were
plated in each of the 12-well plates and allowed to attach
overnight. Porcine myocd and ankrd1 (ankyrin repeat domain 1
protein) were amplified from piglet LV oligo-dT-primed cDNA,
cloned into p3XFLAG-CMV-14 (Sigma, Madrid, Spain) vectors,
verified by sequencing, and purified as previously described
[24,34]. Each batch of COS-7 cells was co-transfected with
plasmids expressing: (1) either pSilencer 2.1-U6 puro myocd sh-RNA
or pSilencer 2.1-U6 puro scramble sh-RNA vectors, (2) FLAG-
tagged pig myocd-B, and (3) FLAG-tagged pig ankrd1 constructions.
All transfections were carried out with Lipofectamine LTX and
PLUS Reagents (Invitrogen, Barcelona, Spain) following the
manufacturer’s instructions. For each combination of plasmids,
two separate transfection assays were employed, and in each assay,
transfections were performed in duplicate. Transfected cells were
cultured for 9 hours, then culture media were replaced with fresh
media supplemented with 10% FBS. The cells were harvested at
Figure 1. Experimental designs. (A) Eight-day-old piglets were randomized in seven groups, assigned to receive doxorubicin (Dox) or isotonic
saline vehicle (PBS) and used in the following experimental series: (1) DHF model (Group I and II), (2) myocd silencing in non-failing piglets (Group III
and IV), and (3) myocd silencing in failing DHF piglets (Group V, VI, VII). Black arrows – intramyocardial delivery of myocd-silencing (sh-1554) or
scrambled (sh-scr1) vectors. X-crossed circle – day of sacrifice. (B) Schematic localization of short hairpin (sh-195–sh-2311) target sites (grey) within
the coding region of pig myocd (GenBank accession number NM_213745). Translation initiation (ATG) and termination (TAG) codons are shown. (C)
Short hairpin template design. The 59 ends of the two strands (sense-antisense) are non-complementary and form the BamH I and Hind III restriction
site overhangs. The short hairpin inserts and their orientation were confirmed by vector sequencing (as exampled here with the sh1554 vector).
doi:10.1371/journal.pone.0026392.g001
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24–48 hours after transfection and processed for RNA and protein
extraction [34,35]. PAOSMCs were cultivated in accordance with
the ECACC recommendations (Cell Applications Inc., San Diego,
US) in P311–500 growth medium (Sigma, Madrid, Spain), until
80% confluency was reached, and then transfected with myocd-
silencing or scramble sh-vectors essentially as described above for
COS-7 cells. The sh-RNA-expressing populations were selected
with puromycin (Invitrogen, Barcelona, Spain) at the concentra-
tion of 1.0 mg/ml. Stable transfectants were grown in the presence
of 1.0 mg/ml of puromycin for 6 days and then processed for RNA
and protein extraction.
Intramyocardial transfection in vivo
In accordance with experimental design (see Fig. 1), naked
plasmids expressing sh-myocd-1554 or sh-scr1 constructions were
delivered into the LV free wall (LVFW) of Dox- and PBS-injected
piglets. Transcatheter, intramyocardial delivery was performed
using a protocol developed and validated in our laboratory [24].
Briefly, under anesthesia and automatic ventilatory support, a
fiber-optic catheter (Cardio-Optics Inc., Boulder, US) and
endoscopic cannula were introduced into the left chest cavity.
Then, the endoscopic needle was introduced into the cannula, and
3–4 intramyocardial injections were performed in the ventro-
lateral area of the LVFW under video-assisted real-time
visualization. On the 2nd and 7th day post-delivery, ECG, LV-
ESP and LV-EDP parameters were measured in piglets as
described above. All these procedures were conducted by
personnel blinded to the experimental design. Then animals were
euthanized and the hearts were rapidly excised, weighed, and
photographed. The ventral LVFW of each heart was sectioned
into 3–4 regions (corresponding to the injection sites) which were
then assayed individually for DNA, RNA and protein isolation.
Semiquantitative PCR
To study the level and persistence of plasmid DNA in
transfected piglet myocardium, total DNAs were isolated from
LV samples of Dox-injected piglets on day 2 and 7 post-delivery
using the Qiagen DNeasy Kit (Qiagen, Madrid, Spain). The level
of plasmid DNA in extracted total DNAs was quantified using
semiquantitative PCR with primers surrounding the sh-insert in
the pSilencer 2.1-U6 puro vector that amplify a fragment of
predicted size (532 bp; see Table 2). PCR was performed in a
Biometra II system (Gottingen, Germany) using the U2 gene as an
internal standard. The amount of DNA and the number of cycles
were varied for each primer pair to ensure amplification within the
linear phase. PCR products were visualized on 2% agarose gels by
ethidium bromide staining and relative band intensity was
estimated by densitometry (VersaDoc 1000) and Quantity One
software (Bio-Rad, Hercules, US).
Quantitative real-time RT-PCR
Four mg of RNA were reverse transcribed using SuperScript III
reverse transcriptase (Invitrogen, Barcelona, Spain) and oligo-dT
primer according to the manufacturer’s instructions. Two-step
quantitative real-time RT-PCR (qPCR) was performed on a Bio-
Rad IQ5 detection system (Bio-Rad, Hercules, US) with SYBR
Green I mix following conditions previously described [24,34].
The reference rpl19 (ribosomal protein L19) gene was amplified to
normalize expression. For each RNA sample, genomic DNA
contamination was determined by PCR on a no-RT control for
the rpl19 gene. Within each experiment, PCR reactions were done
in duplicate. Each PCR reaction was evaluated using melting
curve analysis and checking the PCR products on 8% SYBR
Green-stained polyacrylamide gels. Fold changes were calculated
using the CT method. Data were analyzed using IQ5 optical
Table 1. Oligonucleotides used for constructing short-hairpin RNAs.
Target region Nucleotide sequence
195-S GATCCGCACAAGGTCAGAAACAGGTTCAAGAGACCTGTTTCTGACCTTGTGCTTTTTTGGAAA
195-AS AGCTTTTCCAAAAAAGCACAAGGTCAGAAACAGGTCTCTTGAACCTGTTTCTGACCTTGTGCG
424-S GATCCGTGAGTCTCTCCAAATCAGTTCAAGAGACTGATTTGGAGAGACTCACTTTTTTGGAAA
424-AS AGCTTTTCCAAAAAAGTGAGTCTCTCCAAATCAGTCTCTTGAACTGATTTGGAGAGACTCACG
777-S GATCCGGTGAAGAAGCTCAAGTACTTCAAGAGAGTACTTGAGCTTCTTCACCTTTTTTGGAAA
777-AS AGCTTTTCCAAAAAAGGTGAAGAAGCTCAAGTACTCTCTTGAAGTACTTGAGCTTCTTCACCG
786-S GATCCGCTCAAGTACCACCAGTATTTCAAGAGAATACTGGTGGTACTTGAGCTTTTTTGGAAA
786-AS AGCTTTTCCAAAAAAGCTCAAGTACCACCAGTATTCTCTTGAAATACTGGTGGTACTTGAGCG
950-S GATCCGCTCAGCTCAAGGAACCAATTCAAGAGATTGGTTCCTTGAGCTGAGCTTTTTTGGAAA
950-AS AGCTTTTCCAAAAAAGCTCAGCTCAAGGAACCAATCTCTTGAATTGGTTCCTTGAGCTGAGCG
962-S GATCCGGAACCAAATGAACAGATGTTCAAGAGACATCTGTTCATTTGGTTCCTTTTTTGGAAA
962-AS AGCTTTTCCAAAAAAGGAACCAAATGAACAGATGTCTCTTGAACATCTGTTCATTTGGTTCCG
1116-S GATCCGGTCTCCGAGTTAAGACAATTCAAGAGATTGTCTTAACTCGGAGACCTTTTTTGGAAA
1116-AS AGCTTTTCCAAAAAAGGTCTCCGAGTTAAGACAATCTCTTGAATTGTCTTAACTCGGAGACCG
1554-S GATCCGCAGAAGGTGATCAACGAGTTCAAGAGACTCGTTGATCACCTTCTGCTTTTTTGGAAA
1554-AS AGCTTTTCCAAAAAAGCAGAAGGTGATCAACGAGTCTCTTGAACTCGTTGATCACCTTCTGCG
2169-S GATCCGCAGCAAATGACTCGGAGTTTCAAGAGAACTCCGAGTCATTTGCTGCTTTTTTGGAAA
2169-AS AGCTTTTCCAAAAAAGCAGCAAATGACTCGGAGTTCTCTTGAAACTCCGAGTCATTTGCTGCG
SCR1-S GATCCGCCCGCAAATCGTCTAATCTTCAAGAGAGATTAGACGATTTGCGGGCTTTTTTGGAAA
SCR1-AS AGCTTTTCCAAAAAAGCCCGCAAATCGTCTAATCTCTCTTGAAGATTAGACGATTTGCGGGCG
S - sense, AS – antisense.
doi:10.1371/journal.pone.0026392.t001
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system software 2.0 and CT comparative analysis. For primer
sequences used in qPCR analysis, please see Table 2.
Antibodies
Rabbit polyclonal antibodies to transgelin (TAGLN; ab14106),
phospholamban (PLN; ab15000), SM-a-actin (ACTA2; ab5694),
SM-myosin heavy chain 2 (MYH11; ab53219), SM-calponin
(CNN1; ab46794), cardiac troponin I (TNNI; ab47003), cardiac
calsequestrin-2 (CASQ2; ab3516), and glyceraldehyde 3 phos-
phate dehydrogenase (GAPDH; ab9485) were purchased from
Abcam (Cambridge, UK). Mouse polyclonal antibodies to SM-c-
actin 2 (ACTG2; abA01) were purchased from Novus Biologicals
(Litteton, CO, US). Rabbit polyclonal antibodies to MYOCD
(marked by us as AB531; [24]) were generated by Davids
Biotechnologie (Regenburg, Germany) using the recombinant
TAD-containing fragment of porcine MYOCD as immunogen.
The AB531 antibodies were shown to be specific for both
MYOCD-A (minor) and MYOCD-B (major) variants identified to
date in pig cardiac and SM-containing tissues [24]. Mouse
monoclonal anti-FLAG antibodies and secondary peroxidase-
conjugated anti-rabbit and anti-mouse IgG (Fab-specific) antibod-
ies were purchased from Sigma (Madrid, Spain).
SDS-PAGE and Western blotting
Tissue/cell samples were homogenized and solubilized in
standard 26 Laemmli buffer (Invitrogen, Barcelona, Spain)
supplemented with complete protease inhibitor cocktail (Roche,
Madrid, Spain) as previously described [30,35]. Following
centrifugation at 20,000 g for 30 minutes, the concentration of
supernatant proteins was analyzed using the Bio-Rad DC Protein
Assay Kit (Bio-Rad, Hercules, US) according to the manufactur-
er’s protocol. All samples were stored at 280uC before
electrophoresis. Protein supernatants (5–10 mg/run or 25–30 mg/
run for MYOCD detection) were subjected to SDS-PAGE (Mini-
Protean-III, Bio-Rad, Hercules, US), stained with Coomassie R-
250 (Merck, Barcelona, Spain) or blotted onto PVDF-membranes
(Hybond-P, Amersham Biosciences, Barcelona, Spain). Molecular
weight (MW) standards (Precision Plus Protein WesternC
Standards from Bio-Rad or SeeBlue Plus2 Pre-Stained Standard
from Invitrogen) were included on each gel. Blots were probed
with the antibodies indicated above and visualized by the Super-
Signal West Pico chemiluminescent substrate (Pierce Biotechnol-
ogy, Madrid, Spain) as described [30]. Equivalence of protein
loading was confirmed by Amido-Black (Merck, Barcelona, Spain)
staining of blots after immunodetection. Quantification of Western
Table 2. Primers used in this study.
Primer Target Sequence (59-39) PCR product Application
330 U2 TCGCTTCTCGGCCTTTTGGCT
331 U2 GTACTGCAATACCAGGTCGATG 330-331: 168 bp PCR
356 pSilencer AGGCGATTAAGTTGGGTAACGC
357 pSilencer GGAATTAATACGACTCACTATAGGGAGA 356-357: 532 bp PCR
271 myocd-B CAGGTGTGCAGCAAAAGATGGT
270 myocd CCGAAACTGCTGAGGCTGACT 271-270:105 bp qPCR
272 myocd-A GGTGTGCACTGCACAGATGGT
270 myocd CCGAAACTGCTGAGGCTGACT 272-270: 104 bp qPCR
64 rpl19 CTGCTCAGAAGATACCGTGAAT
206 rpl19 GCTTGTGGATGTGCTCCATGA 64-206:121 bp qPCR
341 srf AGCCTCATGCAGCTGCCTACTA
340 srf GTGCACCTGTATGGCCTGTAC 341-340: 87 bp qPCR
349 myh11 AAACTGCAGGCTCAGATGAAGGA
348 myh11 TGGCTTTCTTCTCATTCTCTTTGG 349-348:103 bp qPCR
82 nppb GCTCCTGCTCCTGTTCTTGCA
251 nppb GGTCCAGCAGCTCCTGTATC 82-251:107 bp qPCR
pSilencer - pSilencer 2.1-U6 puro vector; nppb – gene coding for natriuretic peptide B.
doi:10.1371/journal.pone.0026392.t002
Table 3. Upregulation of HF markers/risk factors in the piglet DHF model.
Gene coding for Gene symbol Fold change p-value Cardiac overexpression Reference
Resistin RETN 27.81 0.01 maladaptive [59,60]
Brain-derived neutrophic factor BDNF 18.26 0.04 adaptive [61]
S100 calcium binding protein A1 S100A1 15.40 0.02 adaptive [62]
Brain natriuretic peptide BNP 12.77 0.05 adaptive [63,64]
Matrix metallopeptidase 9 MMP9 7.63 0.01 maladaptive [65]
Tumor necrosis factor-alpha TNFa 6.30 0.01 risk factor of HF [66]
Alpha-2-macroglobulin a2M 4.06 0.01 marker of HF [67]
doi:10.1371/journal.pone.0026392.t003
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blot signals was obtained by using a Bio-Rad GS800 calibrated
densitometer with Quantity One software.
Statistics
Results are expressed as mean6SEM. Statistical significance
was evaluated by Student’s t-test. Statistical analyses were
performed with SPSS 13 software. A value of p#0.05 was
considered statistically significant.
Results
The myocardin-dependent smooth-muscle gene
program is activated in diastolic failing heart
Neonatal piglets injected with Dox (see Fig. 1; Group I) develop
a cardiotoxic cardiomyopathy that rapidly progresses to diastolic
dysfunction with elevated filling pressures (measured as LV-EDP)
and ECG abnormalities such as ST/T wave depression and low-
voltage QRS complexes. LV-ESP was slightly lower (with
preserved cardiac output index) in Dox-injected compared to
PBS-injected piglets (data not shown). In addition, experimental
piglets showed a substantial decrease in survival between 12 and
20 days after Dox-injection ([30] and this work, see Fig. 1A, Series
1). In the LV myocardium 20 days after Dox administration, DNA
microarray analysis revealed a high upregulation of established HF
markers/risk factors, with a significant fold change ranging from
4.06 (alpha-2-macroglobulin) to 27.81 (resistin) in Dox-injected as
compared to PBS-injected piglets (Table 3). Detailed results of
microarray analysis will be reported elsewhere.
Myocd mRNA levels, measured by microarray followed by
qPCR analyses, were 2-3-fold higher in failing versus non-failing
LV myocardium, whereas srf expression levels remained un-
changed (Fig. 2A). At the protein level (Fig. 2B), a more than
twofold increase in MYOCD was observed in Dox-injected
animals compared to controls. As expected [24], AB531 anti-
MYOCD antibodies revealed a large MYOCD-B variant in LV-
myocardium samples (with the MYOCD-A level being generally
under Western blot sensitivity limits).
This upregulation of myocd expression, at both the mRNA and
protein levels, was associated with increased protein expression of
MYOCD/SRF downstream SM-targets (CNN1, MYH11,
ACTA2, ACTG2, and TAGLN) in failing versus non-failing
myocardium. In addition, the relative level of phospholamban
(PLN - a putative myocd target; see [36,37]) also increased in failing
myocardium. The amounts of CASQ2 and TNNI (key regulatory
proteins of cardiac muscle contraction and relaxation) were not
significantly changed in the LV-myocardium of Dox-injected
compared to PBS-injected animals. In addition, as revealed by
microarray analysis, the expression of genes encoding cardiac
muscle alpha actin (ACTC1), beta-myosin heavy chain (MYH7),
and myosin light chain 2 ventricular (MLC2v) was not affected in
Dox-injected animals.
These results indicated that the activation of myocd and SM-
marker genes is among the prominent features of failing
myocardium and, therefore, the reduction of myocd expression
could be an approach that would allow us to specifically target the
expression of SM-marker genes in our model of DHF-like
syndrome.
Plasmid-based myocardin-specific short-hairpins
effectively inhibit myocardin gene expression in
cell-based and in vivo assays
Nine sh-RNAs were designed against the porcine myocd-B
RNA. Effects of plasmid-based sh-myocd vectors on myocd
expression were first tested in COS7 cells which did not express
the endogenous myocd gene. Each batch of COS7 cells was co-
transfected with the three vectors indicated (Fig. 3A) and the level
of FLAG-tagged MYOCD protein was determined in total cell
lysates by Western blot with monoclonal anti-FLAG antibodies.
Although to varying degrees, all sh-myocd vectors were able to
reduce MYOCD protein levels as compared to sh-scrambled (sh-
scr) controls. FLAG-tagged ANKRD1 levels were uniform in all
samples, indicating efficient transfection and the absence of
nonspecific inhibitory or toxic effects on overall transgene
expression. Two sh-myocd vectors (sh-424 and sh-1554) provoked
a nearly complete inhibition of MYOCD protein expression in
co-transfected COS7 cells.
The inhibitory efficiency of these sh-myocd vectors was then
evaluated by using a primary PAOSMC line, because we found that
these proliferating cells exhibit a proper expression of myocd mRNA
and protein at levels sufficient for analysis. Results of transient
transfection of PAOSMCs revealed that sh-1554 exhibits more
inhibitory activity on myocd expression than sh-424 (data not shown).
The sh-1554 vector was therefore used for permanent transfection of
PAOSMCs. Stable sh-1554 and sh-scr1 transfectants were screened
for MYOCD and its SM-target proteins by immunoblotting. As
shown in Fig. 3B (lane 3), one of the stablemyocd sh-1554 transfectants
displayed a nearly complete knockdown of MYOCD protein
expression. Although none of the sh-1554 transfectants showed
complete MYOCD depletion, the average inhibition of MYOCD
protein expression was more than 80% from the sh-scr1 transfectant
level. This MYOCD inhibition was associated with decreased levels
of ACTA2 (the average inhibition – 88%) and MYH11 (the average
inhibition – 60%) proteins in sh-1554 versus sh-scr1 transfectants,
being expression of TAGLN unaffected (Fig. 3B, C).
The sh-1554 vector was used in downstream experiments on
myocd silencing in non-failing piglet heart in vivo. To this end, PBS-
injected piglets (see Fig. 1A) were intramyocardially transfected
with sh-1554 (Group III) or sh-scr1 (Group IV) vectors. The
spatial distribution of cardiac gene transfer following injection via
the transcutaneously inserted catheter (see Materials and Methods)
has been previously reported [24,34]. Intramyocardial delivery of
sh-1554 reduced (at day 2 post-transfection) the expression of
endogenous myocd-A and myocd-B mRNAs by 75% and 60%,
respectively, which, in turn, decreased the level of the myh11
mRNA (40%) (Fig. 4A). In addition, this silencing of myocd mRNA
expression resulted in a marked decrease of protein levels of
MYOCD itself, as well as, of MYH11, ACTA2, and PLN in sh-
1554-transfected compared to sh-scb1-transfected myocardium
(Fig. 4B). These inhibitory effects seem to be selective because no
changes were detected for TNNI, CASQ2, and GAPDH in sh-
1554 versus sh-scr1 transfections. The most unexpected (and
probably functionally relevant) finding was that LV-ESP (an
accepted marker for end-systolic performance) was slightly but
significantly increased in sh-1554-transfected piglets as compared
to controls (Fig. 4C).
Figure 2. Expression of myocardin and SM-marker genes is activated in diastolic failing heart. (A) Average relative myocd and srf mRNA
levels in failing (Dox) versus non-failing (PBS) LV-myocardium samples, as revealed by microarray and qPCR analyses. (B) Representative Western blots
and an average fold increase in MYOCD and SM-marker protein levels in failing (Dox) over non-failing (PBS) LV-myocardium samples. Black arrows -
MW values (kDa) of the bands detected. Protein load (Amido-Black stained blot after immunodetection). *p#0.05.
doi:10.1371/journal.pone.0026392.g002
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Figure 3. Selection of effective short hairpin constructs against pig myocardin in cell-based assays. (A) Total protein lysates from COS-7
cells co-transfected with FLAG-tagged MYOCD, FLAG-tagged ANKRD1 and indicated sh-myocd (sh-195–sh-2311) or scrambled (sh-scr1, sh-scr2)
vectors were electrophoresed and immunoblotted with anti-FLAG antibodies. Protein load – Amido-Black stained blot after immunodetection. 36–
250 – MW values, kDa. (B) Total protein lysates from PAOSMCs permanently transfected with sh-scr1 (lane 1, 2) or sh-1554 (lane 3, 4) vectors were
screened for MYOCD and SM-marker proteins by immunoblotting. MW values (kDa) of the bands detected are shown. Protein load – Amido-Black
stained blot after immunodetection. (C) Average fold decrease in levels of MYOCD and SM-marker (ACTA2, MYH11, and TAGLN) proteins in sh-1554-
transfected versus sh-scr1-transfected PAOSMCs. *p#0.05.
doi:10.1371/journal.pone.0026392.g003
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On the basis of results obtained from cell-based and in vivo test-
systems, the interfering sh-1554 vector was chosen as the most
promising shRNA for silencing myocd expression in diastolic failing
heart in vivo.
Inhibition of upregulated myocardin expression in
diastolic failing heart results in partial restoration of
cardiac function
To test whether inhibition of MYOCD signaling could influence
the evolution of diastolic dysfunction in the piglet model of DHF,
the following experimental design was used (see Fig. 1A). First, 8-
day-old neonatal piglets were injected with Dox or PBS (Group V,
VI, and VII). At day 13 after the injection, Dox-treated animals
were separated in two groups designated to receive intramyocar-
dial injections of sh-1554 (i.e., Dox/sh-1554 animals) or sh-scr1
vectors (i.e., Dox/sh-scr1 animals), whereas PBS-treated piglets
were intramyocardially injected with sh-scr1 vector (i.e., PBS/sh-
scr1 piglets). Molecular and functional consequences of targeted
myocd inhibition were examined in experimental versus control
groups two and seven days after transfection.
On day 2 post-delivery, MYOCD knockdown resulted in a
significant decrease in the level of both myocd-A (80%) and myocd-B
(75%) mRNAs in failing LV-myocardium of the Dox/sh-1554
piglets as compared to that in the Dox/sh-scr1 animals (Fig. 5A).
In addition, the resulting level of myocd transcript expression in
failing myocardium of the Dox/sh-1554 group was lower (50% the
average decrease) than that in the control PBS/crb1 group
(Fig. 5B). Immunoblot analysis confirmed the myocd-specific
downregulation observed at the mRNA level: the MYOCD
protein content was the lowest in the Dox/sh-1554 group as
compared to controls (Fig. 6).
Next we measured expression of myocd-dependent SM-marker
genes in Dox-failing myocardium transfected with myocd-silencing
vector (see Fig. 6). Compared with Dox-failing myocardium
transfected with scrambled vector (Dox/sh-scr1), protein levels
were highly decreased for CNN1, TAGLN, MYH11, ACTG2 and
ACTA2 in failing myocardium transfected with myocd-silencing
vector (Dox/sh-1554 animals). Even more importantly, the
reduced levels of these SM-marker proteins in Dox/sh-1554
piglets became comparable to those in control animals (PBS/sh-
scr1 group). These effects of myocd silencing were not the
consequence of a general, non-specific impairment of protein
expression in transfected myocardium, because the protein content
of TNNI, CASQ2 and GAPDH was equal in all groups studied.
To assess the effect of myocd silencing on heart function, we used
hemodynamic, ECG and intracardiac pressure measurements 2
days after transfection (Table 4). Elevated LV-EDP values,
characteristic of impaired diastolic function in the Dox/scr1
group, were significantly decreased in failing hearts transfected
with myocd-silencing vector (Dox/sh-1554 group) to values similar
to those in hearts of PBS-treated piglets (PBS/sh-scr1 group). The
re-establishment of impaired diastolic function was associated with
lowering the rate of ECG-indicators of myocardial ischemia (ST/
T depression, decreased QRS voltage) as well as with the trend
toward amelioration of bradycardia in Dox/sh-1554 compared to
Dox/sh-scr1 transfected piglets (Fig. 5C). In addition, and in
concordance with the above stated evidence (see Fig. 4C), myocd
Figure 4. Silencing of myocardin expression in non-failing piglet myocardium in vivo. Healthy PBS-injected piglets (see Fig. 1A) were
intramyocardially transfected with myocd-silencing (sh-1554) or control scrambled (sh-scr1) vectors. (A) Levels of myocd-A, myocd-B and myh11
mRNAs detected by qPCR. (B) Representative Western blots of MYOCD, MYH11, ACTA2, PLN, TNNI3, CASQ2, and GAPDH. (C) LV-ESP and LV-EDP
values in sh-scr1- and sh-1554-transfected animals. *p#0.05.
doi:10.1371/journal.pone.0026392.g004
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silencing resulted in slightly augmented LV-ESP values (i.e.,
systolic performance) in Dox-failing piglets (see Table 4). Hemo-
dynamic measurements were not significantly different between
groups with the exception of slightly higher heart rhythm and
lower systolic blood pressure values in Dox/sh-1554 compared to
control Dox/sh-scr1 and PBS/sh-scr1 group, respectively.
Figure 5. Inhibition of endogenous myocardin expression in failing myocardium of Dox-injected piglets two days after myocd-
RNAi-vector delivery. (A) Representative qPCR analysis of endogenous myocd-A and myocd-B expression in failing LV-myocardium transfected
with myocd silencing (Dox+sh-1554; blue plots) or scrambled (Dox+sh-scr1; red plots) vectors, and in non-failing LV-myocardium transfected with sh-
scr1 vector (PBS+sh-scr1; green plots). Myocd mRNA levels (normalized to the internal standard rpl19) were measured in three LV-samples, each
derived from an individual animal. CT - cycle threshold; DCT - differences in threshold cycles for target and reference. Calculated fold-change in myocd
expression is shown. FT - fluorescence threshold. NTC - non-template controls. (B) Average relative decrease in themyocd-A/B transcript level in failing
myocardium transfected with sh-1554 (blue) vector as compared to that in failing (red) and non-failing (green) myocardium transfected with sh-scr1
vector. *p#0.05. # Not significant. (C) Representative ECG recordings (AVL lead) from Dox-injected piglets intramyocardially transfected by myocd
silencing (Dox+sh-1554) or scrambled (Dox+sh-scr1) vectors.
doi:10.1371/journal.pone.0026392.g005
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Figure 6. Lowering levels of SM-marker proteins in failing myocardium of Dox-injected piglets two days after myocd-RNAi-vector
delivery. (A) Representative Western blots of MYOCD, CNN1, TAGLN, MYH11, ACTG2, ACTA2, TNNI3, CASQ2, and GAPDH in failing LV-myocardium
transfected with scrambled (Dox+sh-scr1; lane 1, 2) ormyocd silencing (Dox+sh-1554; lane 3, 4) vectors, and in non-failing LV-myocardium transfected
with sh-scr1 vector (PBS+sh-scr1; lane 5, 6). Each LV-sample (1–6) was derived from an individual animal. MW values (kDa) of the bands detected are
shown. (B) Overall relative levels of SM-marker proteins in LV-samples as based on average values from each group studied. *p#0.05. # Not
significant.
doi:10.1371/journal.pone.0026392.g006
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Taken together, the data demonstrated that at an early time
point (on day 2 post-delivery), myocd inhibition improves
functioning of failing hearts. At this time point, we also observed
a decline in BNP mRNA expression in failing LV-myocardium
transfected with myocd-silencing vector compared to controls (see
Table 4).
The efficacy of plasmid-based (non-viral) vectors can be
compromised by a rapid degradation of delivered plasmid
constructions in vivo [38]. In this work, at day 7 post-delivery,
the level of plasmid DNA in transfected LV-myocardium was an
average 10-fold lower as compared to 2 days after administration,
and it was detected at near quantification limit in 3 out of 8
examined piglets (Fig. 7A, B). These results suggested that the
degree of plasmid-based silencing of myocd expression also drops,
leading to the restoration of upregulated levels of myocd in failing
myocardium at distant time points after transfection.
At day 7 post-delivery, as revealed by qPCR analysis, the
endogenous myocd mRNA expression in the Dox/sh-1554 group
was re-activated (with the exception of one animal; see Fig. 7C,
plot 5) to a level comparable to that in the failing control animals
that received the scrambled vector (Dox/sh-scr1 group) (Fig. 7D).
At the protein level, myocd expression in experimental animals was
also similar to that of Dox-treated controls showing a reduced
MYOCD content in only one of eight Dox/sh-1554 transfected
piglets (Fig. 6E, lane 5 and Fig. 6F). Such re-activation of myocd
expression was associated with an almost full return of ACTG2
and the partial restoration of MYH11 protein levels in failing
myocardium of Dox/sh-1554 piglets as compared with those in
failing control animals that received the scrambled vector (i.e.,
Dox/sh-scr1 group; see Fig. 6E).
Subsequent functional analysis of Dox/sh-1554 transfected
piglets at day 7 post-delivery demonstrated that a return to
elevated myocd expression levels is associated with the re-
deterioration of diastolic function (elevated LV-EDP values) as
compared with the same experimental run at day 2 post-delivery
(see Table 4). These results suggested that a reactivation of
MYOCD signaling cascade after myocd inhibition burst is
maladaptive particularly in terms of LV diastolic function.
Nevertheless, in spite of a return to elevated myocd expression
and impaired diastolic function at day 7 after transfection, failing
piglets receiving the myocd-silencing vector were characterized by
higher LV-ESP, less frequency of ischemic ECG-manifestations,
and higher survival rate as compared with failing piglets
transfected with scrambled vector. Of note, higher LV-ESP values
in Dox+sh-1554 versus Dox+sh-scr1 groups, both after two and
seven days, suggested a beneficial effect of myocd-targeting in
preserving LV function (see Table 4).
Collectively, the results strongly suggest that a mild inhibition of
myocd, at advanced stages of experimental DHF, downregulates the
activated expression of SM-marker genes in failing LV-myocar-
dium associated with partial restoration of diastolic function and
lower premature mortality of DHF-piglets compared to controls.
Discussion
The association between activated MYOCD signaling and HF
has been established in studies of ventricular myocardium in
animal models and in human myocardium from patients with end-
stage HF undergoing heart transplantation [19,21]. Pathological
forms of ventricular hypertrophy were also found to be associated
with an aberrantly elevated expression of myocd and with severe
downregulation of competitive inhibitors of MYOCD in ventric-
ular myocardium [25]. Moreover, myocd is upregulated in blood
mononuclear cells of patients with hypertrophic cardiomyopathy
[39].
The present work was undertaken in an attempt to integrate
upregulated MYOCD signaling into the pathogenesis of HF, using
targeted RNAi-mediated myocd gene inhibition in the porcine
model of DHF. Our model of Dox-induced DHF in neonatal
piglets is justifiably suitable for a given context-of-use and task,
since in this model the development of diastolic dysfunction is
Table 4. Cardiac parameters of piglets injected with Dox or PBS followed by intramyocardial delivery of myocd-specific or
scramble short-hairpin plasmids.
Parameter on day 2 post-delivery on day 7 post-delivery
PBS+sh-scr1 Dox+sh-scr1 Dox+sh-1554 Dox+sh-scr1 Dox+sh-1554
Transfected animals,
n
6 8 10 8 8
Survived animals, n 6 7 10 4 8
HR, beats/min 12465 10664* 13665 123610 13066
Systolic BP, mm Hg 69.061.4 61.562.0 55.863.5 71.565.6 68.061.6
Diastolic BP, mm Hg 47.063.0 44.061.5 40.863.2 57.064.6{ 46.062.1
H/B ratio61000 6.760.1 7.360.3 7.760.3 6.960.6 6.860.3
LVES pressure, mm
Hg
7161.0 6164.5* 7462.6 57.563.5{ 66.862.4
LVED pressure, mm
Hg
8.561.3 13.060.2* 9.561.2 12.561.2 12.360.9
ST/T depression, % 0 100 50 100 80
Low-voltage QRS, % 0 100 20 100 40
LV BNP mRNA,
relative value
1.060.3 6.260.8* 3.760.6 7.761.2 6.761.4
PBS - phosphate-buffered saline; Dox - doxorubicin; sh-scr1 - scramble shRNA expression plasmid 1; sh-1554 - myocardin-specific shRNA expression plasmid; HR - heart
rhythm; BP - blood pressure; H/B - heart/body ratio; LVES and LVED - left ventricle end systolic and diastolic pressure values, respectively; ST/T and ORS - ECG values
(leads I, II, and AVL). p#0.05: Dox+sh-scr1 versus Dox+sh-1554, 2 days (*) and 7 days ({) post-delivery.
doi:10.1371/journal.pone.0026392.t004
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associated with the exaggerated activation of myocd and down-
stream SM-targets in failing hearts (see Fig. 2). Of note, the
expression of some SRF-dependent sarcomeric genes (such as
ACTC1, MYH7, and TNNI) was not affected in Dox-injected
piglets.
To the best of our knowledge, this is the first indication of
activation of a SM-gene program in DHF, the pathological
condition resulting from increased stiffness and impaired relaxation
of ventricular myocardium that is associated with alterations in
myofilament and calcium handling proteins (reviewed in [40,41]).
In this sense, we found that levels of PLN (a key regulator of
sarco-endoplasmic reticulum Ca2+-ATPase) are elevated in
DHF piglets (see Fig. 2). In large animal models, overexpression
of PLN in the heart resulted in altered myocardial structure [42]
whereas PLN inhibition reversed HF progression [43]. In this
work, a mild silencing of myocd in healthy neonatal piglets
resulted in a concomitant decrease in the expression of MYH11,
ACTA2, and PLN that, in turn, was associated with an increase,
although not highly significant, of end-systolic performance (see
Fig. 4C). Formally viewed, these data are well in line with our
previous results that in vivo forced expression of myocd in LV-
myocardium impaired systolic performance in neonatal pig
heart [24]. Only further studies will refine these findings and
reveal to what extent modulations of myocd expression in the
fast-growing neonatal myocardium could contribute to cardiac
performance.
Figure 7. Recovery of endogenous myocardin expression in failing myocardium of Dox-injected piglets 7 days after myocd-RNAi-
vector delivery. (A) Representative ethidium bromide-stained gel showing detection of plasmid DNA in LV-samples harvested from Dox-failing
piglets two (lane 1–5) and six (lane 6–10) days after intramyocardial delivery of myocd-silencing (sh-1554) plasmid vector. U2 gene expression was
used as an internal standard. (B) Relative levels of plasmid DNA in LV-samples as based on average values from each group studied. *p#0.05. (C)
Representative qPCR analysis of endogenous myocd-B mRNA levels in failing LV-myocardium transfected with myocd silencing (sh-1554; red plots) or
scrambled (sh-scr1; blue plots) vectors. Other details as in the caption to Fig. 5A. (D) Overallmyocd-BmRNA levels in sh-1554-transfected as compared
with scr1-transfected failing piglets. # Not significant. (E) Representative Western blots of MYOCD, MYH11, and ACTG2 in failing LV-myocardium
transfected with scrambled (sh-scr1; lane 1–3) or myocd silencing (sh-1554; lane 4–6) vectors. Each LV-sample (1–6) was derived from an individual
animal. MW values (kDa) of the bands detected are shown. (F) MYOCD protein levels in LV-samples as based on average values from each group
studied. # Not significant.
doi:10.1371/journal.pone.0026392.g007
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The moderate reduction (60–70%) of ventricular myocd activity
observed in these experiments did not lead to any deterioration of
cardiac function in neonatal piglets, as one could have expected
from previous studies, where cardio-restricted myocd knockdown
(85%) was found to induce dilated cardiomyopathy and fatal HF
in postnatal mice [17]. These significant differences in the cardiac
phenotypes of sh-myocd-transfected and genetically myocd-depleted
postnatal hearts can be explained by many factors on multiple
levels. As compared to myocd gene ablation, a moderate sh-
mediated inhibition of myocd expression: (1) did not lead to the
almost complete loss of the targeted mRNA (i.e., residual
expression of myocd) in the LV-myocardium and (2) did not affect
myocd activity in other cardiac chambers (data not shown). In
addition, species-specific differences in MYOCD requirements for
postnatal LV-remodeling, in pigs as compared to mice, could not
be excluded, although the underlying mechanisms remain elusive
at present.
Distinct splice variants of myocd were reported to be expressed in
mammalian heart [13,19,44,45,46,47] with the myocd B transcript
being more abundant in pig ventricular myocardium [24]. In this
work, a pool of potential sh-RNAs complementary to different
regions of the porcine myocd-B mRNA was generated, and after
validation in three distinct experimental setups, the sh-interfering
RNA1554 was chosen as the most promising sequence for
silencing myocd in DHF, because it effectively targets the
endogenous pool of myocd-A/B mRNAs in both pig aortic SM-
cells in vitro (see Fig. 3B) and normal piglet LV-myocardium in vivo
(see Fig. 4A).
We explored the potential role of myocd inhibition in the piglet
heart during HF progression by direct delivery of the myocd-specific
silencing plasmid (i.e., sh-1554 plasmid, see Fig. 1C) into failing
LV-myocardium. Comparative analysis of gene expression and
functional consequences of myocd silencing at different time
intervals (i.e., on day 2 and 7 after delivery; see Table 4) revealed
the following noteworthy observations: (1) the early moderate
inhibition of endogenous myocd expression attenuated expression of
SM-marker genes in failing LV-myocardium, (2) this decrease of
MYOCD signaling activity in failing myocardium to the level
comparable with that in non-failing animals resulted in improve-
ment of impaired diastolic function and amelioration of myocar-
dial ischemic conditions, (3) the posterior restoration of elevated
myocd expression led to activation of myocd-dependent SM-marker
genes in failing LV-myocardium associated with a return to altered
diastolic function, and (4) the transient inhibition of MYOCD
signaling at advanced stages of DHF delayed the progression of
diastolic dysfunction and extended the survival of failing piglets. In
rats, myocardial ischemia and bradycardia are two ECG-
manifestations of the acute Dox-induced cardiotoxicity, embodied
with decreased heart rhythm [48]. In our model of Dox-induced
DHF, myocd targeting was associated with amelioration of such
ECG-manifestations suggesting an involvement of MYOCD
signaling in the regulation of cardiac function.
It is not unreasonable to suggest that impaired diastolic function
in Dox-treated piglets is conditioned, at least in part, by
overexpression of SM-marker genes (CNN1, TAGLN, MYH11,
ACTG2, and ACTA2) in failing myocardium. The induction of
these SM-marker genes seems not to be associated with activation
of srf expression because srf transcript levels were not changed in
failing as compared to non-failing piglet myocardium. Thus, it is
tempting to speculate that the activation of SM-marker genes in
DHF myocardium can be attributed, at least in part, to selective
upregulation of MYOCD. In cardiomyocytes, the level and
functional activity of MYOCD is regulated by a balance of positive
[21,22,49] and negative [25,50,51,52] factors. In this sense, our
present results can be interpreted as suggesting that failing
ventricular myocardium is characterized by impaired counterbal-
ance of MYOCD factors resulting in the overexpression of SM-
marker genes, a functionally maladaptive response [53].
Myocd overexpression correlates with a wide array of patholog-
ical conditions. Upregulation of myocd enforces cardiac hypertro-
phic response [21,22,25], antagonizes cell proliferation in growth-
and tumor-related processes [54,55,56], and in some situations
promotes hypercontractile vascular phenotype that may contribute
to neurovascular dysfunction [57,58]. Given that elevated
expression of myocd is a frequent event in HF conditions
[19,21,25], our results highlight the benefits of inhibiting the
upregulated MYOCD signaling pathway in failing ventricular
myocardium: a moderate myocd suppression was sufficient to
downregulate the elevated expression of MYOCD-dependent SM-
marker genes, ameliorate diastolic chamber dysfunction, and
prevent pre-mature mortality of DHF animals.
More broadly, the results of the present work give a clear
indication that adjusting altered myocd expression to the range of
physiological variation could be essential in order to reduce and
normalize the expression of SRF/MYOCD-dependent SM-
marker genes, that are upregulated in advanced HF of diverse
etiologies ([27,28,29]; this work), without compromising the
physiological functions of MYOCD signaling [17] as a part of
the adaptive response of the heart to stress.
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